Theravance Biopharma TBPH Return on invested capital

Return on invested capital at other companies

Gyre Therapeutics, Inc.GYRE

-26.7%-32.7pp

Royalty PharmaRPRX

8.7%-2.7pp

Zevra Therapeutics, Inc.ZVRA

71.7%+48.7pp

Aurinia PharmaceuticalsAUPH

33.7%+20.8pp

Mirum Pharmaceuticals, Inc.MIRM

-43.3%—

Pulmonx CorporationLUNG

-92.1%+42.9pp

FAQ

What is Theravance Biopharma's return on invested capital?

Theravance Biopharma (TBPH) reported return on invested capital of 1.5% in Q1 2026.

How has Theravance Biopharma's return on invested capital changed year-over-year?

Theravance Biopharma's return on invested capital increased by 104.6% year-over-year, from -33.2% to 1.5%.

What is the long-term trend for Theravance Biopharma's return on invested capital?

Over 2 years (2023 to 2025), Theravance Biopharma's return on invested capital has grown at a -75.2% compound annual growth rate (CAGR), from -26.8% to -1.6%.

What does return on invested capital mean?

Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.